# Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

* The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile.
* CEO notes that “the FDA’s decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.”
* Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing.

 Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions.

 The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy in reducing oral aphthous ulcers and a favorable safety profile in patients with Behçet’s disease (https://ibn.fm/idr7M). The designation not only highlights the promise of…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-advances-rare-disease-treatment-with-fda-orphan-designation/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/fda-grants-orphan-drug-status-to-soligenix-s-dusquetide-for-behcet-s-disease/791b148d2edb29d01a9cb1bc32c92b80) 


Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202509/196514-soligenix-erhalt-fda-orphan-drug-designation-fur-dusquetide-zur-behandlung-von-behcet-krankheit)
 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1n8jquj/fda_grants_orphan_drug_status_to_soligenixs/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/4/hushT9MA.webp)